ABL Diagnostics, a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories, has announced today the release of new DeepChek® assays intended to be used for Influenza A, Influenza B, Respiratory Syncytial Virus (RSV) A and Respiratory Syncytial Virus B genotyping.
The assays, available in kit format, complete a portfolio of applications dedicated to the analysis of respiratory viruses, including SARS-CoV-2 Whole Genome sequencing (DeepChek® Whole Genome SARS-CoV-2 Genotyping) and the simultaneous qualitative detection and differentiation of SARS-CoV-2, Influenza A virus, Influenza B virus, and/or Respiratory Syncytial Virus RNA (UltraGene Assay Combo 4 Screening – CE IVD).
The release of the assays comes as healthcare systems across the northern hemisphere prepare for the “tripledemic” of flu, SARS-CoV-2, and RSV infections, with the Respiratory Syncytial Virus (RSV) diagnostic market expected to register a significant CAGR of 10.1% during 2023 – 2028.
Dr. Sofiane Mohamed, Head of R&D at ABL Diagnostics said: “Our team keeps developing new applications on a regular basis with the objective of releasing end products matching as many settings as possible. As such, we have verified those new assays on several sequencing platforms and made sure RSV and Influenza samples can be multiplexed with other types of specimens within a single NGS run, to ensure maximal efficiency.”
Dimitri Gonzalez, Head of Diagnostics at ABL Diagnostics added: “Innovation is part of the ABL Diagnostics DNA, we aim to consolidate our portfolio of applications and release new kits in line with our partners and customers’ expectations. Since the COVID-19 pandemic, we have learned the need to keep studying and tracking respiratory viruses and gathering knowledge and epidemiology information. There are many national and international programs to sequence RSV and Flu. We have answered successfully the first challenges and se requirements to fulfil daily research activities”.
ABL Diagnostics develops and markets molecular biology products on a worldwide basis, primarily focusing on HIV, SARS-CoV-2, Tuberculosis, viral hepatitis B and C, 16s/18s RNA for taxonomy and microbiome analyses and other viral and bacterial targets.
The company also develops, manufactures, and markets kits for clinical specimen collection – MediaChek® and digital solutions like Nadis®, an CE-marked Electronic Medical Record (EMR) system used in France in more than 200 hospitals managing patients infected by HIV or Viral Hepatitis.
ABL Diagnostics is a public company listed in compartment B of Euronext’s regulated market in Paris (Euronext: ABLD – ISIN: FR001400AHX6).
Today, ABL Diagnostics has announced the release of new DeepChek® assays for Influenza A, Influenza B, Respiratory Syncytial Virus (RSV) A and Respiratory Syncytial Virus B genotyping. The assays, available in kit format, complete a portfolio of applications dedicated to the analysis of respiratory viruses, including SARS-CoV-2 Whole Genome sequencing and the simultaneous qualitative detection and differentiation of SARS-CoV-2, Influenza A virus, Influenza B virus, and/or Respiratory Syncytial Virus RNA.
This release comes as healthcare systems across the northern hemisphere prepare for the “tripledemic” of flu, SARS-CoV-2, and RSV infections, with the Respiratory Syncytial Virus (RSV) diagnostic market expected to register a significant CAGR of 10.1% during 2023 – 2028.
Dr. Sofiane Mohamed, Head of R&D at ABL Diagnostics said: “Our team keeps developing new applications on a regular basis with the objective of releasing end products matching as many settings as possible. As such, we have verified those new assays on several sequencing platforms and made sure RSV and Influenza samples can be multiplexed with other types of specimens within a single NGS run, to ensure maximal efficiency.”
ABL Diagnostics develops and markets molecular biology products on a worldwide basis, primarily focusing on HIV, SARS-CoV-2, Tuberculosis, viral hepatitis B and C, 16s/18s RNA for taxonomy and microbiome analyses and other viral and bacterial targets. The company also develops
